Axsome Therapeutics, Inc. (AXSM) is listed on NASDAQ in Pharmaceutical Stocks. It is $199.01, -3.52%, with a $10.4B market cap. RSI is 34.8, near oversold. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 34.8 Near Oversold
Market Cap $10.4B
Volume 372.5K
Fundamentals — 10-Q Q2 2026
Revenue $409.6M
Net Income $-115.9M
EPS $-2.25
Operating Margin -27.6%
Net Margin -28.3%
Debt / Equity 1.4x
P/E Ratio -88.4x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Tabuteau Herriot | Chief Executive Officer | Sell | 49,664 | $212.19 | $10.5M | 2026 Aug 6 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 49,666 | $240.25 | $11.9M | 2026 Jul 1 |
| Jeffs Roger | Insider | Sell | 572 | $247.65 | $141,656 | 2026 Jun 11 |
| Mahony Susan | Insider | Sell | 600 | $241.69 | $145,017 | 2026 Jun 10 |
| Coleman Mark | Insider | Sell | 643 | $249.00 | $160,107 | 2026 Jun 10 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 49,670 | $241.01 | $12.0M | 2026 Jun 9 |
| Pizzie Nick | Chief Financial Officer | Sell | 33,000 | $240.09 | $7.9M | 2026 Jun 9 |
| Coleman Mark | Insider | Sell | 17,537 | $229.20 | $4.0M | 2026 Jun 2 |
| Jacobson Mark L. | Chief Operating Officer | Sell | 4,750 | $227.95 | $1.1M | 2026 May 5 |
| Maizel Ari | Chief Commercial Officer | Sell | 7,500 | $182.42 | $1.4M | 2026 Apr 22 |
| Coleman Mark | Insider | Sell | 25,000 | $161.11 | $4.0M | 2026 Feb 26 |
| Jacobson Mark L. | Chief Operating Officer | Sell | 35,378 | $161.88 | $5.7M | 2026 Feb 26 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 79,973 | $145.66 | $11.6M | 2025 Dec 4 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 163,939 | $133.07 | $21.8M | 2025 Nov 5 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 45,384 | $119.38 | $5.4M | 2025 Oct 8 |
| Jacobson Mark L. | Chief Operating Officer | Sell | 10,000 | $115.96 | $1.2M | 2025 Sep 22 |
| Jacobson Mark L. | Chief Operating Officer | Sell | 45,783 | $114.48 | $5.2M | 2025 Sep 16 |
| Tabuteau Herriot | Chief Executive Officer | Sell | 62,880 | $117.08 | $7.4M | 2025 Sep 16 |
| Coleman Mark | Director | Buy | 1,575 | $127.28 | $200,466 | 2025 Sep 8 |
| Saad Mark E | Director | Sell | 9,127 | $125.07 | $1.1M | 2025 Sep 5 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $534.20 | 52.0 | $12.3B |
| | $16.34 | 45.3 | $18.8B |
| | $113.32 | 33.7 | -- |
| | $90.36 | 35.0 | $8.0B |
Take AXSM further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put AXSM in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Axsome Therapeutics, Inc. next reports.
Set alerts on AXSM
Get notified when Axsome Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free